Adjuvant chemotherapy plus 52 weeks of trastuzumab is the current standard regimen for HER2+ early breast cancer (Costa et al. 2010; Garnock-Jones et al. 2010; Gianni et al. 2011). The gene discussed is ERBB2; the disease is breast carcinoma.